SCHEMBL16592154

SCHEMBL16592154

COc1cccc(OCc2nc(C)cc(=O)n2C)c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.60
TP53 P04637 6/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
ALDH1A1 P00352 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MAPT P10636 5/20 0.51
RAB9A P51151 2/20 0.51
GLA P06280 1/20 0.51
KMT2A Q03164 1/20 0.51
THRB P10828 1/20 0.50
PPARG P37231 1/20 0.49
POLB P06746 2/20 0.49
HTR2C P28335 3/20 0.48
MAOA P21397 1/20 0.48
FFAR1 O14842 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15583974 0.86 MAOB (0.61) MAOBALDH1A1RAB9APPARGHTR2C
SCHEMBL16592145 0.86 HTR2C (0.64) MAOBSMN1; SMN2TDP1MAPTRAB9A
SCHEMBL15583972 0.85 MAPT (0.51) MAOBTP53SMN1; SMN2ALDH1A1TDP1
SCHEMBL16589273 0.84 MAPT (0.48) MAOBTP53SMN1; SMN2ALDH1A1TDP1
SCHEMBL15583971 0.83 HTR2C (0.53) MAOBTP53SMN1; SMN2RAB9APPARG
SCHEMBL16592148 0.83 HTR2C (0.67) MAOBRAB9APPARGHTR2CMAOA
SCHEMBL16592147 0.79 PPARG (0.47) MAOBTDP1RAB9APPARGHTR2C
SCHEMBL16592150 0.77 MAOA (0.44) MAOBRAB9APPARGHTR2CMAOA
SCHEMBL16592155 0.75 HTR2C (0.43) MAOBALDH1A1PPARGHTR2CMAOA
SCHEMBL16592159 0.74 MAOB (0.48) MAOBALDH1A1PPARGHTR2CMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434695-B2 Nitrogenous heterocyclic derivatives and their application in drugs SUNSHINE LAKE PHARMA CO., LTD (CN) 2016-09-06 US disclosed
US-20150087639-A1 Nitrogenous Heterocyclic Derivatives And Their Application In Drugs SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087639-A1 Nitrogenous Heterocyclic Derivatives And Their Application In Drugs TNNC1, TNNI3, IAPP MAOB 383/4885TP53 477/4885SMN1; SMN2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.